Archive · 7 Jan 2026
Corona Remedies Expands into Infertility and New Therapies
Corona Remedies is a big medicine company in India.
They recently bought some products from Bayer to help people with infertility problems.
They are going to start selling these products soon and have a special team to talk to doctors about them.
Over the next few years, they also plan to make medicines for other health issues like spine problems, skin problems, and more.
This will help them become even stronger in the medicine market.
Corona Remedies is expanding into the infertility market by acquiring six brands from Bayer India.
The company plans to launch a specialized infertility sales team with fewer than 50 medical representatives.
Corona Remedies aims to enter five new therapy areas, including spine, rheumatology, CNS, dermatology, and gastroenterology, over the next 3-5 years.
The acquired Bayer brands, such as Fostine, Luprofact, Menodac, and Ovidac, are currently under clinical and market validation.
The company is strengthening its core infertility therapy portfolio, expected to be rolled out in the next couple of months.
- Who
- Corona Remedies, an Ahmedabad-based pharmaceutical company
- What
- Expansion into infertility and five new therapy areas
- When
- Next 3-5 years, with infertility launches starting this year
- Where
- India
- Why
- To strengthen its market position and diversify its product portfolio
- Company
- Corona Remedies
- Location
- Ahmedabad, India
- New Therapy Areas
- Infertility, spine, rheumatology, CNS, dermatology, gastroenterology
- Acquired Brands
- Fostine, Luprofact, Menodac, Ovidac, Spye, Vageston
- Specialist Team Size
- Fewer than 50 medical representatives
- Expected Launch Timeline
- Next 3-5 years
- Current Market Position
- Top 30 in Indian pharmaceutical market
- Core Focus Areas
- Women’s healthcare, cardio-diabeto, pain management, urology